Moreover, the most effective treatment for each of these types may differ, for example, breast cancers that are growing in response to HER2 (human epidermal growth factor receptor 2 protein) can be treated with the targeted therapy drug trastuzumab, while ER+ (oestrogen hormone receptor positive) cancers may respond to hormone therapy that blocks oestrogen, on the other hand, triple negative (hormone receptor negative and HER2 negative) cancers do not respond to targeted therapy nor hormone therapy but respond to chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.